nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—CYP3A4—Bexarotene—hematologic cancer	0.0463	0.0829	CbGbCtD
Rifaximin—CYP3A4—Lomustine—hematologic cancer	0.0431	0.0771	CbGbCtD
Rifaximin—CYP3A4—Busulfan—hematologic cancer	0.0431	0.0771	CbGbCtD
Rifaximin—CYP3A4—Thiotepa—hematologic cancer	0.0384	0.0687	CbGbCtD
Rifaximin—CYP3A4—Methoxsalen—hematologic cancer	0.0298	0.0534	CbGbCtD
Rifaximin—CYP3A4—Bortezomib—hematologic cancer	0.0284	0.0508	CbGbCtD
Rifaximin—CYP3A4—Daunorubicin—hematologic cancer	0.0271	0.0486	CbGbCtD
Rifaximin—CYP3A4—Cytarabine—hematologic cancer	0.0239	0.0429	CbGbCtD
Rifaximin—CYP3A4—Teniposide—hematologic cancer	0.0236	0.0422	CbGbCtD
Rifaximin—CYP3A4—Ifosfamide—hematologic cancer	0.0218	0.039	CbGbCtD
Rifaximin—CYP3A4—Imatinib—hematologic cancer	0.0208	0.0372	CbGbCtD
Rifaximin—CYP3A4—Ruxolitinib—hematologic cancer	0.0196	0.0351	CbGbCtD
Rifaximin—CYP3A4—Nilotinib—hematologic cancer	0.0189	0.0338	CbGbCtD
Rifaximin—CYP3A4—Vinorelbine—hematologic cancer	0.0187	0.0335	CbGbCtD
Rifaximin—CYP3A4—Triamcinolone—hematologic cancer	0.0171	0.0307	CbGbCtD
Rifaximin—CYP3A4—Dasatinib—hematologic cancer	0.0167	0.0299	CbGbCtD
Rifaximin—CYP3A4—Mitoxantrone—hematologic cancer	0.0165	0.0295	CbGbCtD
Rifaximin—CYP3A4—Betamethasone—hematologic cancer	0.0147	0.0263	CbGbCtD
Rifaximin—CYP3A4—Prednisolone—hematologic cancer	0.0145	0.026	CbGbCtD
Rifaximin—CYP3A4—Prednisone—hematologic cancer	0.0137	0.0245	CbGbCtD
Rifaximin—CYP3A4—Irinotecan—hematologic cancer	0.013	0.0233	CbGbCtD
Rifaximin—CYP3A4—Vinblastine—hematologic cancer	0.0115	0.0207	CbGbCtD
Rifaximin—CYP3A4—Vincristine—hematologic cancer	0.0114	0.0203	CbGbCtD
Rifaximin—CYP3A4—Etoposide—hematologic cancer	0.0104	0.0186	CbGbCtD
Rifaximin—CYP3A4—Dexamethasone—hematologic cancer	0.00855	0.0153	CbGbCtD
Rifaximin—Rifabutin—HSP90AA1—hematologic cancer	0.00727	0.768	CrCbGaD
Rifaximin—CYP3A4—Doxorubicin—hematologic cancer	0.0071	0.0127	CbGbCtD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—ABCC3—hematologic cancer	0.00267	0.0911	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—hematologic cancer	0.00194	0.0662	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—RARA—hematologic cancer	0.00177	0.0605	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—hematologic cancer	0.00153	0.0523	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—RARA—hematologic cancer	0.0014	0.0478	CbGpPWpGaD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—ABCB1—hematologic cancer	0.00136	0.0463	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—NR0B2—hematologic cancer	0.0013	0.0445	CbGpPWpGaD
Rifaximin—Rifampicin—ABCC3—hematologic cancer	0.00107	0.112	CrCbGaD
Rifaximin—CYP3A4—Aflatoxin B1 metabolism—EPHX1—hematologic cancer	0.000975	0.0332	CbGpPWpGaD
Rifaximin—Rifampicin—UGT1A1—hematologic cancer	0.000921	0.0972	CrCbGaD
Rifaximin—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—hematologic cancer	0.000797	0.0272	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—AR—hematologic cancer	0.000793	0.027	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—hematologic cancer	0.00078	0.0266	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—NR3C1—hematologic cancer	0.000641	0.0219	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—AR—hematologic cancer	0.000626	0.0214	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ZNF552—hematologic cancer	0.000609	0.0208	CbGpPWpGaD
Rifaximin—CYP3A4—Codeine and Morphine Metabolism—ABCC3—hematologic cancer	0.000564	0.0193	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—ESR1—hematologic cancer	0.000544	0.0186	CbGpPWpGaD
Rifaximin—CYP3A4—Codeine and Morphine Metabolism—UGT1A1—hematologic cancer	0.000531	0.0181	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—NR3C1—hematologic cancer	0.000507	0.0173	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—ESR1—hematologic cancer	0.00043	0.0147	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—UGT1A1—hematologic cancer	0.000339	0.0116	CbGpPWpGaD
Rifaximin—CYP3A4—Farnesoid X Receptor  Pathway—NR0B2—hematologic cancer	0.000332	0.0113	CbGpPWpGaD
Rifaximin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—hematologic cancer	0.00031	0.0106	CbGpPWpGaD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC3—hematologic cancer	0.000309	0.0105	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—ABCG2—hematologic cancer	0.000294	0.01	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—ZNF552—hematologic cancer	0.000293	0.00999	CbGpPWpGaD
Rifaximin—CYP3A4—Codeine and Morphine Metabolism—ABCB1—hematologic cancer	0.000287	0.00979	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—UGT1A1—hematologic cancer	0.000277	0.00946	CbGpPWpGaD
Rifaximin—CYP3A4—Farnesoid X Receptor  Pathway—FGF19—hematologic cancer	0.00025	0.00852	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—RARA—hematologic cancer	0.000242	0.00826	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NR0B2—hematologic cancer	0.000225	0.00768	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—hematologic cancer	0.000224	0.00765	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—CASC3—hematologic cancer	0.000222	0.00757	CbGpPWpGaD
Rifaximin—Rifampicin—ABCB1—hematologic cancer	0.000215	0.0227	CrCbGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NCOR2—hematologic cancer	0.000203	0.00693	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—NQO1—hematologic cancer	0.00019	0.00648	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—hematologic cancer	0.000186	0.00635	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—hematologic cancer	0.000177	0.00605	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—hematologic cancer	0.000175	0.00597	CbGpPWpGaD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—hematologic cancer	0.000157	0.00536	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—GSTM1—hematologic cancer	0.000146	0.00497	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RARS—hematologic cancer	0.000143	0.00488	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—hematologic cancer	0.000137	0.00466	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—POLR3E—hematologic cancer	0.000135	0.00459	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—PARP1—hematologic cancer	0.000129	0.00441	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RARA—hematologic cancer	0.000117	0.00398	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—TET2—hematologic cancer	0.000117	0.00398	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RPLP1—hematologic cancer	0.000114	0.0039	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	0.000113	0.00385	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NR0B2—hematologic cancer	0.000108	0.0037	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—AR—hematologic cancer	0.000108	0.00369	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—DNMT3A—hematologic cancer	0.000103	0.00353	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—ELL—hematologic cancer	0.000102	0.00348	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—CDKN2B—hematologic cancer	9.97e-05	0.0034	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NCOR2—hematologic cancer	9.79e-05	0.00334	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	9.47e-05	0.00323	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NCOR1—hematologic cancer	9.46e-05	0.00323	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—hematologic cancer	9.02e-05	0.00308	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AGO2—hematologic cancer	9.02e-05	0.00308	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	8.96e-05	0.00306	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—DNMT3B—hematologic cancer	8.84e-05	0.00301	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—H3F3B—hematologic cancer	8.84e-05	0.00301	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NR3C1—hematologic cancer	8.75e-05	0.00298	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—RPS14—hematologic cancer	8.08e-05	0.00276	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NUP98—hematologic cancer	7.96e-05	0.00271	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NUP214—hematologic cancer	7.67e-05	0.00262	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	7.52e-05	0.00257	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—ESR1—hematologic cancer	7.43e-05	0.00253	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	7.42e-05	0.00253	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NOTCH1—hematologic cancer	7.18e-05	0.00245	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—EIF4EBP1—hematologic cancer	7.07e-05	0.00241	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HSPB1—hematologic cancer	7.07e-05	0.00241	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—SMC1A—hematologic cancer	6.77e-05	0.00231	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—H3F3A—hematologic cancer	6.63e-05	0.00226	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—CREBBP—hematologic cancer	6.51e-05	0.00222	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—EZH2—hematologic cancer	6.36e-05	0.00217	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PARP1—hematologic cancer	6.23e-05	0.00212	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—HDAC2—hematologic cancer	6.01e-05	0.00205	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AR—hematologic cancer	5.21e-05	0.00178	CbGpPWpGaD
Rifaximin—Rhinitis—Doxorubicin—hematologic cancer	5e-05	0.000124	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—hematologic cancer	4.99e-05	0.000124	CcSEcCtD
Rifaximin—Hypersensitivity—Prednisolone—hematologic cancer	4.96e-05	0.000123	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—hematologic cancer	4.96e-05	0.000123	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—hematologic cancer	4.95e-05	0.000123	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—hematologic cancer	4.93e-05	0.000122	CcSEcCtD
Rifaximin—Urticaria—Triamcinolone—hematologic cancer	4.92e-05	0.000122	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—hematologic cancer	4.91e-05	0.000122	CcSEcCtD
Rifaximin—Asthenia—Etoposide—hematologic cancer	4.9e-05	0.000122	CcSEcCtD
Rifaximin—Body temperature increased—Triamcinolone—hematologic cancer	4.9e-05	0.000122	CcSEcCtD
Rifaximin—Anaphylactic shock—Prednisone—hematologic cancer	4.9e-05	0.000122	CcSEcCtD
Rifaximin—Angiopathy—Epirubicin—hematologic cancer	4.89e-05	0.000122	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—hematologic cancer	4.89e-05	0.000121	CcSEcCtD
Rifaximin—Decreased appetite—Betamethasone—hematologic cancer	4.89e-05	0.000121	CcSEcCtD
Rifaximin—Decreased appetite—Dexamethasone—hematologic cancer	4.89e-05	0.000121	CcSEcCtD
Rifaximin—Nausea—Mitoxantrone—hematologic cancer	4.88e-05	0.000121	CcSEcCtD
Rifaximin—Nausea—Irinotecan—hematologic cancer	4.88e-05	0.000121	CcSEcCtD
Rifaximin—Infection—Prednisone—hematologic cancer	4.86e-05	0.000121	CcSEcCtD
Rifaximin—Mediastinal disorder—Epirubicin—hematologic cancer	4.86e-05	0.000121	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.85e-05	0.000121	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.85e-05	0.000121	CcSEcCtD
Rifaximin—Back pain—Methotrexate—hematologic cancer	4.85e-05	0.00012	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	4.85e-05	0.00165	CbGpPWpGaD
Rifaximin—Fatigue—Dexamethasone—hematologic cancer	4.85e-05	0.00012	CcSEcCtD
Rifaximin—Fatigue—Betamethasone—hematologic cancer	4.85e-05	0.00012	CcSEcCtD
Rifaximin—Pruritus—Etoposide—hematologic cancer	4.83e-05	0.00012	CcSEcCtD
Rifaximin—Shock—Prednisone—hematologic cancer	4.82e-05	0.00012	CcSEcCtD
Rifaximin—Pain—Dexamethasone—hematologic cancer	4.81e-05	0.000119	CcSEcCtD
Rifaximin—Pain—Betamethasone—hematologic cancer	4.81e-05	0.000119	CcSEcCtD
Rifaximin—Nervous system disorder—Prednisone—hematologic cancer	4.8e-05	0.000119	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—CDKN2B—hematologic cancer	4.8e-05	0.00164	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	4.78e-05	0.00163	CbGpPWpGaD
Rifaximin—Skin disorder—Prednisone—hematologic cancer	4.76e-05	0.000118	CcSEcCtD
Rifaximin—Nausea—Gemcitabine—hematologic cancer	4.75e-05	0.000118	CcSEcCtD
Rifaximin—Vomiting—Cisplatin—hematologic cancer	4.74e-05	0.000118	CcSEcCtD
Rifaximin—Hyperhidrosis—Prednisone—hematologic cancer	4.73e-05	0.000118	CcSEcCtD
Rifaximin—Mental disorder—Epirubicin—hematologic cancer	4.72e-05	0.000117	CcSEcCtD
Rifaximin—Rash—Cisplatin—hematologic cancer	4.7e-05	0.000117	CcSEcCtD
Rifaximin—Dermatitis—Cisplatin—hematologic cancer	4.7e-05	0.000117	CcSEcCtD
Rifaximin—Malnutrition—Epirubicin—hematologic cancer	4.69e-05	0.000117	CcSEcCtD
Rifaximin—Diarrhoea—Etoposide—hematologic cancer	4.67e-05	0.000116	CcSEcCtD
Rifaximin—Anorexia—Prednisone—hematologic cancer	4.67e-05	0.000116	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—hematologic cancer	4.65e-05	0.000116	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—hematologic cancer	4.65e-05	0.000116	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—hematologic cancer	4.63e-05	0.000115	CcSEcCtD
Rifaximin—Feeling abnormal—Betamethasone—hematologic cancer	4.63e-05	0.000115	CcSEcCtD
Rifaximin—Feeling abnormal—Dexamethasone—hematologic cancer	4.63e-05	0.000115	CcSEcCtD
Rifaximin—Flushing—Doxorubicin—hematologic cancer	4.63e-05	0.000115	CcSEcCtD
Rifaximin—Flatulence—Epirubicin—hematologic cancer	4.62e-05	0.000115	CcSEcCtD
Rifaximin—Gastrointestinal pain—Betamethasone—hematologic cancer	4.6e-05	0.000114	CcSEcCtD
Rifaximin—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.6e-05	0.000114	CcSEcCtD
Rifaximin—Hypersensitivity—Triamcinolone—hematologic cancer	4.57e-05	0.000113	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	4.56e-05	0.00155	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NCOR1—hematologic cancer	4.55e-05	0.00155	CbGpPWpGaD
Rifaximin—Back pain—Epirubicin—hematologic cancer	4.54e-05	0.000113	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—hematologic cancer	4.53e-05	0.000112	CcSEcCtD
Rifaximin—Malaise—Methotrexate—hematologic cancer	4.52e-05	0.000112	CcSEcCtD
Rifaximin—Dizziness—Etoposide—hematologic cancer	4.52e-05	0.000112	CcSEcCtD
Rifaximin—Muscle spasms—Epirubicin—hematologic cancer	4.51e-05	0.000112	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—hematologic cancer	4.51e-05	0.000112	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	4.5e-05	0.00153	CbGpPWpGaD
Rifaximin—Mediastinal disorder—Doxorubicin—hematologic cancer	4.5e-05	0.000112	CcSEcCtD
Rifaximin—Urticaria—Dexamethasone—hematologic cancer	4.47e-05	0.000111	CcSEcCtD
Rifaximin—Urticaria—Betamethasone—hematologic cancer	4.47e-05	0.000111	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.46e-05	0.000111	CcSEcCtD
Rifaximin—Dizziness—Prednisolone—hematologic cancer	4.46e-05	0.000111	CcSEcCtD
Rifaximin—Asthenia—Triamcinolone—hematologic cancer	4.45e-05	0.00011	CcSEcCtD
Rifaximin—Body temperature increased—Dexamethasone—hematologic cancer	4.44e-05	0.00011	CcSEcCtD
Rifaximin—Abdominal pain—Betamethasone—hematologic cancer	4.44e-05	0.00011	CcSEcCtD
Rifaximin—Body temperature increased—Betamethasone—hematologic cancer	4.44e-05	0.00011	CcSEcCtD
Rifaximin—Abdominal pain—Dexamethasone—hematologic cancer	4.44e-05	0.00011	CcSEcCtD
Rifaximin—Nausea—Cisplatin—hematologic cancer	4.43e-05	0.00011	CcSEcCtD
Rifaximin—Insomnia—Prednisone—hematologic cancer	4.43e-05	0.00011	CcSEcCtD
Rifaximin—Pruritus—Triamcinolone—hematologic cancer	4.38e-05	0.000109	CcSEcCtD
Rifaximin—Cough—Methotrexate—hematologic cancer	4.38e-05	0.000109	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—hematologic cancer	4.37e-05	0.000109	CcSEcCtD
Rifaximin—Ill-defined disorder—Epirubicin—hematologic cancer	4.35e-05	0.000108	CcSEcCtD
Rifaximin—Vomiting—Etoposide—hematologic cancer	4.34e-05	0.000108	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—hematologic cancer	4.34e-05	0.000108	CcSEcCtD
Rifaximin—Anaemia—Epirubicin—hematologic cancer	4.34e-05	0.000108	CcSEcCtD
Rifaximin—Rash—Etoposide—hematologic cancer	4.31e-05	0.000107	CcSEcCtD
Rifaximin—Dermatitis—Etoposide—hematologic cancer	4.3e-05	0.000107	CcSEcCtD
Rifaximin—Headache—Etoposide—hematologic cancer	4.28e-05	0.000106	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—hematologic cancer	4.28e-05	0.000106	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—hematologic cancer	4.27e-05	0.000106	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—hematologic cancer	4.27e-05	0.000106	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—hematologic cancer	4.27e-05	0.000106	CcSEcCtD
Rifaximin—Decreased appetite—Prednisone—hematologic cancer	4.26e-05	0.000106	CcSEcCtD
Rifaximin—Rash—Prednisolone—hematologic cancer	4.25e-05	0.000106	CcSEcCtD
Rifaximin—Dermatitis—Prednisolone—hematologic cancer	4.24e-05	0.000105	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.24e-05	0.000105	CcSEcCtD
Rifaximin—Malaise—Epirubicin—hematologic cancer	4.23e-05	0.000105	CcSEcCtD
Rifaximin—Fatigue—Prednisone—hematologic cancer	4.22e-05	0.000105	CcSEcCtD
Rifaximin—Headache—Prednisolone—hematologic cancer	4.22e-05	0.000105	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—hematologic cancer	4.22e-05	0.000105	CcSEcCtD
Rifaximin—Vertigo—Epirubicin—hematologic cancer	4.22e-05	0.000105	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NR3C1—hematologic cancer	4.21e-05	0.00144	CbGpPWpGaD
Rifaximin—Syncope—Epirubicin—hematologic cancer	4.21e-05	0.000105	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—hematologic cancer	4.2e-05	0.000104	CcSEcCtD
Rifaximin—Constipation—Prednisone—hematologic cancer	4.19e-05	0.000104	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—hematologic cancer	4.17e-05	0.000104	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—hematologic cancer	4.13e-05	0.000103	CcSEcCtD
Rifaximin—Loss of consciousness—Epirubicin—hematologic cancer	4.12e-05	0.000102	CcSEcCtD
Rifaximin—Dizziness—Triamcinolone—hematologic cancer	4.1e-05	0.000102	CcSEcCtD
Rifaximin—Cough—Epirubicin—hematologic cancer	4.09e-05	0.000102	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—hematologic cancer	4.09e-05	0.000102	CcSEcCtD
Rifaximin—Infection—Methotrexate—hematologic cancer	4.07e-05	0.000101	CcSEcCtD
Rifaximin—Nausea—Etoposide—hematologic cancer	4.06e-05	0.000101	CcSEcCtD
Rifaximin—Feeling abnormal—Prednisone—hematologic cancer	4.04e-05	0.0001	CcSEcCtD
Rifaximin—Asthenia—Dexamethasone—hematologic cancer	4.03e-05	0.0001	CcSEcCtD
Rifaximin—Asthenia—Betamethasone—hematologic cancer	4.03e-05	0.0001	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—hematologic cancer	4.03e-05	0.0001	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	4.02e-05	0.00137	CbGpPWpGaD
Rifaximin—Nervous system disorder—Methotrexate—hematologic cancer	4.01e-05	9.97e-05	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—hematologic cancer	4.01e-05	9.97e-05	CcSEcCtD
Rifaximin—Gastrointestinal pain—Prednisone—hematologic cancer	4e-05	9.95e-05	CcSEcCtD
Rifaximin—Nausea—Prednisolone—hematologic cancer	4e-05	9.94e-05	CcSEcCtD
Rifaximin—Chest pain—Epirubicin—hematologic cancer	4e-05	9.92e-05	CcSEcCtD
Rifaximin—Arthralgia—Epirubicin—hematologic cancer	4e-05	9.92e-05	CcSEcCtD
Rifaximin—Myalgia—Epirubicin—hematologic cancer	4e-05	9.92e-05	CcSEcCtD
Rifaximin—Pruritus—Dexamethasone—hematologic cancer	3.98e-05	9.88e-05	CcSEcCtD
Rifaximin—Pruritus—Betamethasone—hematologic cancer	3.98e-05	9.88e-05	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—hematologic cancer	3.97e-05	9.88e-05	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.97e-05	9.86e-05	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—hematologic cancer	3.96e-05	9.83e-05	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—MTR—hematologic cancer	3.95e-05	0.00135	CbGpPWpGaD
Rifaximin—Discomfort—Epirubicin—hematologic cancer	3.95e-05	9.81e-05	CcSEcCtD
Rifaximin—Vomiting—Triamcinolone—hematologic cancer	3.94e-05	9.79e-05	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—hematologic cancer	3.92e-05	9.73e-05	CcSEcCtD
Rifaximin—Rash—Triamcinolone—hematologic cancer	3.91e-05	9.71e-05	CcSEcCtD
Rifaximin—Dry mouth—Epirubicin—hematologic cancer	3.91e-05	9.71e-05	CcSEcCtD
Rifaximin—Dermatitis—Triamcinolone—hematologic cancer	3.9e-05	9.7e-05	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—hematologic cancer	3.9e-05	9.69e-05	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—hematologic cancer	3.9e-05	9.69e-05	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—hematologic cancer	3.89e-05	9.67e-05	CcSEcCtD
Rifaximin—Urticaria—Prednisone—hematologic cancer	3.89e-05	9.66e-05	CcSEcCtD
Rifaximin—Headache—Triamcinolone—hematologic cancer	3.88e-05	9.64e-05	CcSEcCtD
Rifaximin—Body temperature increased—Prednisone—hematologic cancer	3.87e-05	9.62e-05	CcSEcCtD
Rifaximin—Abdominal pain—Prednisone—hematologic cancer	3.87e-05	9.62e-05	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—MYC—hematologic cancer	3.86e-05	0.00132	CbGpPWpGaD
Rifaximin—Confusional state—Epirubicin—hematologic cancer	3.86e-05	9.59e-05	CcSEcCtD
Rifaximin—Diarrhoea—Dexamethasone—hematologic cancer	3.85e-05	9.56e-05	CcSEcCtD
Rifaximin—Diarrhoea—Betamethasone—hematologic cancer	3.85e-05	9.56e-05	CcSEcCtD
Rifaximin—Anaphylactic shock—Epirubicin—hematologic cancer	3.83e-05	9.51e-05	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—hematologic cancer	3.82e-05	9.5e-05	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—hematologic cancer	3.82e-05	9.48e-05	CcSEcCtD
Rifaximin—Infection—Epirubicin—hematologic cancer	3.8e-05	9.45e-05	CcSEcCtD
Rifaximin—Cough—Doxorubicin—hematologic cancer	3.79e-05	9.41e-05	CcSEcCtD
Rifaximin—Shock—Epirubicin—hematologic cancer	3.77e-05	9.36e-05	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	3.76e-05	0.00128	CbGpPWpGaD
Rifaximin—Nervous system disorder—Epirubicin—hematologic cancer	3.76e-05	9.33e-05	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.73e-05	9.26e-05	CcSEcCtD
Rifaximin—Skin disorder—Epirubicin—hematologic cancer	3.72e-05	9.24e-05	CcSEcCtD
Rifaximin—Dizziness—Dexamethasone—hematologic cancer	3.72e-05	9.24e-05	CcSEcCtD
Rifaximin—Dizziness—Betamethasone—hematologic cancer	3.72e-05	9.24e-05	CcSEcCtD
Rifaximin—Hyperhidrosis—Epirubicin—hematologic cancer	3.7e-05	9.2e-05	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—hematologic cancer	3.7e-05	9.2e-05	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—hematologic cancer	3.7e-05	9.18e-05	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—hematologic cancer	3.7e-05	9.18e-05	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—hematologic cancer	3.7e-05	9.18e-05	CcSEcCtD
Rifaximin—Nausea—Triamcinolone—hematologic cancer	3.68e-05	9.14e-05	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.67e-05	9.12e-05	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—hematologic cancer	3.65e-05	9.07e-05	CcSEcCtD
Rifaximin—Anorexia—Epirubicin—hematologic cancer	3.65e-05	9.07e-05	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—hematologic cancer	3.65e-05	9.06e-05	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—MAPK14—hematologic cancer	3.65e-05	0.00124	CbGpPWpGaD
Rifaximin—Dry mouth—Doxorubicin—hematologic cancer	3.62e-05	8.98e-05	CcSEcCtD
Rifaximin—Hypersensitivity—Prednisone—hematologic cancer	3.61e-05	8.96e-05	CcSEcCtD
Rifaximin—Hypotension—Epirubicin—hematologic cancer	3.58e-05	8.89e-05	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—ESR1—hematologic cancer	3.58e-05	0.00122	CbGpPWpGaD
Rifaximin—Vomiting—Dexamethasone—hematologic cancer	3.58e-05	8.88e-05	CcSEcCtD
Rifaximin—Vomiting—Betamethasone—hematologic cancer	3.58e-05	8.88e-05	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—hematologic cancer	3.57e-05	8.88e-05	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—hematologic cancer	3.56e-05	8.84e-05	CcSEcCtD
Rifaximin—Rash—Dexamethasone—hematologic cancer	3.55e-05	8.81e-05	CcSEcCtD
Rifaximin—Rash—Betamethasone—hematologic cancer	3.55e-05	8.81e-05	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—hematologic cancer	3.54e-05	8.8e-05	CcSEcCtD
Rifaximin—Dermatitis—Dexamethasone—hematologic cancer	3.54e-05	8.8e-05	CcSEcCtD
Rifaximin—Dermatitis—Betamethasone—hematologic cancer	3.54e-05	8.8e-05	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.53e-05	8.78e-05	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—hematologic cancer	3.53e-05	8.77e-05	CcSEcCtD
Rifaximin—Headache—Dexamethasone—hematologic cancer	3.52e-05	8.75e-05	CcSEcCtD
Rifaximin—Headache—Betamethasone—hematologic cancer	3.52e-05	8.75e-05	CcSEcCtD
Rifaximin—Infection—Doxorubicin—hematologic cancer	3.52e-05	8.75e-05	CcSEcCtD
Rifaximin—Asthenia—Prednisone—hematologic cancer	3.51e-05	8.73e-05	CcSEcCtD
Rifaximin—Pain—Methotrexate—hematologic cancer	3.5e-05	8.69e-05	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.49e-05	8.67e-05	CcSEcCtD
Rifaximin—Shock—Doxorubicin—hematologic cancer	3.49e-05	8.66e-05	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—hematologic cancer	3.48e-05	8.63e-05	CcSEcCtD
Rifaximin—Pruritus—Prednisone—hematologic cancer	3.46e-05	8.61e-05	CcSEcCtD
Rifaximin—Insomnia—Epirubicin—hematologic cancer	3.46e-05	8.61e-05	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NOTCH1—hematologic cancer	3.46e-05	0.00118	CbGpPWpGaD
Rifaximin—Skin disorder—Doxorubicin—hematologic cancer	3.44e-05	8.55e-05	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—hematologic cancer	3.43e-05	8.51e-05	CcSEcCtD
Rifaximin—Dyspnoea—Epirubicin—hematologic cancer	3.41e-05	8.48e-05	CcSEcCtD
Rifaximin—Anorexia—Doxorubicin—hematologic cancer	3.38e-05	8.39e-05	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—hematologic cancer	3.37e-05	8.38e-05	CcSEcCtD
Rifaximin—Diarrhoea—Prednisone—hematologic cancer	3.35e-05	8.32e-05	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—hematologic cancer	3.35e-05	8.31e-05	CcSEcCtD
Rifaximin—Nausea—Betamethasone—hematologic cancer	3.34e-05	8.3e-05	CcSEcCtD
Rifaximin—Nausea—Dexamethasone—hematologic cancer	3.34e-05	8.3e-05	CcSEcCtD
Rifaximin—Decreased appetite—Epirubicin—hematologic cancer	3.33e-05	8.27e-05	CcSEcCtD
Rifaximin—Hypotension—Doxorubicin—hematologic cancer	3.31e-05	8.23e-05	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.31e-05	8.21e-05	CcSEcCtD
Rifaximin—Fatigue—Epirubicin—hematologic cancer	3.3e-05	8.2e-05	CcSEcCtD
Rifaximin—Pain—Epirubicin—hematologic cancer	3.27e-05	8.14e-05	CcSEcCtD
Rifaximin—Constipation—Epirubicin—hematologic cancer	3.27e-05	8.14e-05	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—hematologic cancer	3.25e-05	8.08e-05	CcSEcCtD
Rifaximin—Dizziness—Prednisone—hematologic cancer	3.24e-05	8.04e-05	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—hematologic cancer	3.24e-05	8.04e-05	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—hematologic cancer	3.24e-05	8.04e-05	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.23e-05	8.02e-05	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—hematologic cancer	3.21e-05	7.96e-05	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—hematologic cancer	3.16e-05	7.85e-05	CcSEcCtD
Rifaximin—Feeling abnormal—Epirubicin—hematologic cancer	3.16e-05	7.84e-05	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—CREBBP—hematologic cancer	3.13e-05	0.00107	CbGpPWpGaD
Rifaximin—Gastrointestinal pain—Epirubicin—hematologic cancer	3.13e-05	7.78e-05	CcSEcCtD
Rifaximin—Vomiting—Prednisone—hematologic cancer	3.11e-05	7.73e-05	CcSEcCtD
Rifaximin—Rash—Prednisone—hematologic cancer	3.09e-05	7.67e-05	CcSEcCtD
Rifaximin—Dermatitis—Prednisone—hematologic cancer	3.08e-05	7.66e-05	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—hematologic cancer	3.08e-05	7.65e-05	CcSEcCtD
Rifaximin—Headache—Prednisone—hematologic cancer	3.07e-05	7.62e-05	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.06e-05	7.6e-05	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—hematologic cancer	3.06e-05	7.59e-05	CcSEcCtD
Rifaximin—Urticaria—Epirubicin—hematologic cancer	3.04e-05	7.56e-05	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—hematologic cancer	3.03e-05	7.53e-05	CcSEcCtD
Rifaximin—Pain—Doxorubicin—hematologic cancer	3.03e-05	7.53e-05	CcSEcCtD
Rifaximin—Abdominal pain—Epirubicin—hematologic cancer	3.03e-05	7.52e-05	CcSEcCtD
Rifaximin—Body temperature increased—Epirubicin—hematologic cancer	3.03e-05	7.52e-05	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—hematologic cancer	3.02e-05	7.49e-05	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—hematologic cancer	2.94e-05	7.29e-05	CcSEcCtD
Rifaximin—Feeling abnormal—Doxorubicin—hematologic cancer	2.92e-05	7.25e-05	CcSEcCtD
Rifaximin—Nausea—Prednisone—hematologic cancer	2.91e-05	7.23e-05	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.9e-05	7.2e-05	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—hematologic cancer	2.9e-05	7.19e-05	CcSEcCtD
Rifaximin—Hypersensitivity—Epirubicin—hematologic cancer	2.82e-05	7.01e-05	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—hematologic cancer	2.82e-05	6.99e-05	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—hematologic cancer	2.8e-05	6.96e-05	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—hematologic cancer	2.8e-05	6.96e-05	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—hematologic cancer	2.8e-05	6.96e-05	CcSEcCtD
Rifaximin—Asthenia—Epirubicin—hematologic cancer	2.75e-05	6.83e-05	CcSEcCtD
Rifaximin—Pruritus—Epirubicin—hematologic cancer	2.71e-05	6.73e-05	CcSEcCtD
Rifaximin—Dizziness—Methotrexate—hematologic cancer	2.71e-05	6.72e-05	CcSEcCtD
Rifaximin—Diarrhoea—Epirubicin—hematologic cancer	2.62e-05	6.51e-05	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—hematologic cancer	2.61e-05	6.49e-05	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	2.61e-05	0.000889	CbGpPWpGaD
Rifaximin—Vomiting—Methotrexate—hematologic cancer	2.6e-05	6.46e-05	CcSEcCtD
Rifaximin—Rash—Methotrexate—hematologic cancer	2.58e-05	6.41e-05	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—hematologic cancer	2.58e-05	6.4e-05	CcSEcCtD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	2.57e-05	0.000877	CbGpPWpGaD
Rifaximin—Headache—Methotrexate—hematologic cancer	2.56e-05	6.37e-05	CcSEcCtD
Rifaximin—Asthenia—Doxorubicin—hematologic cancer	2.54e-05	6.32e-05	CcSEcCtD
Rifaximin—Dizziness—Epirubicin—hematologic cancer	2.53e-05	6.29e-05	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—hematologic cancer	2.51e-05	6.23e-05	CcSEcCtD
Rifaximin—Vomiting—Epirubicin—hematologic cancer	2.44e-05	6.05e-05	CcSEcCtD
Rifaximin—Nausea—Methotrexate—hematologic cancer	2.43e-05	6.04e-05	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—hematologic cancer	2.42e-05	6.02e-05	CcSEcCtD
Rifaximin—Rash—Epirubicin—hematologic cancer	2.41e-05	6e-05	CcSEcCtD
Rifaximin—Dermatitis—Epirubicin—hematologic cancer	2.41e-05	5.99e-05	CcSEcCtD
Rifaximin—Headache—Epirubicin—hematologic cancer	2.4e-05	5.96e-05	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	2.39e-05	0.000817	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	2.36e-05	0.000806	CbGpPWpGaD
Rifaximin—Dizziness—Doxorubicin—hematologic cancer	2.34e-05	5.82e-05	CcSEcCtD
Rifaximin—Nausea—Epirubicin—hematologic cancer	2.27e-05	5.65e-05	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—hematologic cancer	2.25e-05	5.6e-05	CcSEcCtD
Rifaximin—Rash—Doxorubicin—hematologic cancer	2.23e-05	5.55e-05	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—hematologic cancer	2.23e-05	5.55e-05	CcSEcCtD
Rifaximin—Headache—Doxorubicin—hematologic cancer	2.22e-05	5.52e-05	CcSEcCtD
Rifaximin—Nausea—Doxorubicin—hematologic cancer	2.1e-05	5.23e-05	CcSEcCtD
Rifaximin—CYP3A4—Metabolism—PHYH—hematologic cancer	2e-05	0.000681	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GMPS—hematologic cancer	2e-05	0.000681	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—FTCD—hematologic cancer	2e-05	0.000681	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MAPK3—hematologic cancer	1.91e-05	0.000652	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—MYC—hematologic cancer	1.86e-05	0.000635	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.83e-05	0.000623	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.6e-05	0.000544	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ASNS—hematologic cancer	1.6e-05	0.000544	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—DCK—hematologic cancer	1.6e-05	0.000544	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HDC—hematologic cancer	1.51e-05	0.000516	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CDA—hematologic cancer	1.38e-05	0.000472	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PC—hematologic cancer	1.33e-05	0.000454	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AKT1—hematologic cancer	1.29e-05	0.00044	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GBA—hematologic cancer	1.29e-05	0.000439	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.29e-05	0.000439	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTAP—hematologic cancer	1.18e-05	0.000401	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—FHL2—hematologic cancer	1.05e-05	0.000358	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AGRN—hematologic cancer	1.03e-05	0.000351	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—IDH2—hematologic cancer	9.75e-06	0.000333	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HMMR—hematologic cancer	9.75e-06	0.000333	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ARNTL—hematologic cancer	9.17e-06	0.000313	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CA9—hematologic cancer	8.92e-06	0.000304	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ACP5—hematologic cancer	8.92e-06	0.000304	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NCOR2—hematologic cancer	8.8e-06	0.0003	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—IDH1—hematologic cancer	8.39e-06	0.000286	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTO1—hematologic cancer	8.29e-06	0.000283	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCC3—hematologic cancer	8.29e-06	0.000283	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—TXN—hematologic cancer	8.29e-06	0.000283	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SPHK1—hematologic cancer	8.11e-06	0.000277	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UGT1A1—hematologic cancer	7.8e-06	0.000266	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CRABP1—hematologic cancer	7.58e-06	0.000259	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC22A1—hematologic cancer	7.58e-06	0.000259	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALOX5—hematologic cancer	7.39e-06	0.000252	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NUP98—hematologic cancer	7.16e-06	0.000244	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ADCY7—hematologic cancer	6.95e-06	0.000237	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NCOA3—hematologic cancer	6.95e-06	0.000237	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NUP214—hematologic cancer	6.9e-06	0.000235	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCG2—hematologic cancer	6.76e-06	0.000231	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTR—hematologic cancer	6.76e-06	0.000231	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ENO2—hematologic cancer	6.63e-06	0.000226	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTT1—hematologic cancer	6.43e-06	0.000219	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SDC1—hematologic cancer	6.28e-06	0.000214	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NQO1—hematologic cancer	5.34e-06	0.000182	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CD44—hematologic cancer	5.34e-06	0.000182	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYCS—hematologic cancer	5.06e-06	0.000172	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	5.02e-06	0.000171	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.46e-06	0.000152	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.22e-06	0.000144	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NCOR1—hematologic cancer	4.1e-06	0.00014	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTM1—hematologic cancer	4.1e-06	0.00014	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.62e-06	0.000123	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.04e-06	0.000104	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.82e-06	9.62e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.67e-06	9.12e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALB—hematologic cancer	2.64e-06	9e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.52e-06	8.61e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.33e-06	7.95e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTEN—hematologic cancer	2.01e-06	6.87e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—EP300—hematologic cancer	1.92e-06	6.55e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.42e-06	4.84e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKT1—hematologic cancer	1.16e-06	3.96e-05	CbGpPWpGaD
